

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

**SUPERIOR COURT OF CALIFORNIA,
COUNTY OF LOS ANGELES
JUVENILE DIVISION**

In the Matter of:

Los Angeles County Clients of Children’s
Law Center of California

Minor(s).

DECLARATION OF DR. JAMES
WATT IN SUPPORT OF
CHILDREN’S LAW CENTER OF
CALIFORNIA (CLC) MOTION FOR
MODIFICATION OF
PRESIDING JUDGE’S
STANDING ORDER
REGARDING VISITATION
ISSUED 3/20/20;

I, James Watt, M.D., MPH, declare as follows:

1. I am a resident of the State of California. I am over the age of 18 and have personal knowledge of all the facts stated herein. If called as a witness, I could and would testify competently to the matters set forth below.

2. I am employed as the Acting Deputy Director of the Center for Infectious Diseases and Interim State Epidemiologist at the California Department of Public Health (“CDPH”).

1 3. As the Acting Deputy Director of the Center for Infectious Diseases and Interim
2 State Epidemiologist at CDPH, I coordinate the CDPH’s epidemiologic response to disease
3 outbreaks and emerging health threats.

4 4. Prior to my role as Acting Deputy Director of the Center for Infectious
5 Diseases, I was the Chief of the Division of Communicable Disease Control from 2010 until
6 2019 and Deputy State Epidemiologist from 2012 until 2019 at CDPH. A summary of my
7 professional and employment background is attached as Exhibit A.

8 5. My background is in epidemiology. I completed my residency in pediatrics at
9 in 1993 and obtained a Masters in Public Health in Maternal and Child Health in 1995. In
10 1996, I joined the California Department of Health Services (“CDHS”) as a Public Health
11 Medical Officer II. In 1999, I joined the federal Centers for Disease Control and Prevention
12 (“CDC”) as an Epidemic Intelligence Service Officer in the Respiratory Diseases Branch. In
13 2001, I became an Assistant Scientist in the School of Public Health at John Hopkins
14 University. In 2006, I joined the CDPH has a Public Health Medical Officer III
15 (Epidemiology) and became Chief of the Tuberculosis Control Branch in 2008 and Chief of the
16 Division of Communicable Disease Control in 2010. In 2012, I became Deputy State
17 Epidemiologist at the CDPH. In addition to my current role as Acting Deputy Director of the
18 Center for Infectious Diseases and Interim State Epidemiologist, I am an Associate at the John
19 Hopkins University School of Public Health and Clinical Professor at the University of
20 California, San Francisco, School of Medicine. I have also served on a variety of advisory
21 panels at, among others, the CDHS, CDC, and World Health Organization.

22 6. CDPH is one of sixteen departments and offices within the California Health
23 and Human Services Agency and its fundamental responsibilities include infectious disease
24 control and prevention, food safety, environmental health, laboratory services, patient safety,
25 emergency preparedness, chronic disease prevention and health promotion, family health,
26

1 health equity and vital records and statistics. Our mission is to advance the health and well-
2 being of California's diverse people and communities.

3 7. The Center for Infectious Diseases (CID) protects the people in California from
4 the threat of preventable infectious diseases and assists those living with an infectious disease
5 in securing prompt and appropriate access to healthcare, medications and associated support
6 services.

7 8. I am advising on the COVID-19 response and am familiar with the guidance
8 issued by the CDPH and the State of California Executive Order N-33-20.

9 9. I have reviewed the LA County Superior Court standing order temporarily
10 suspending dependency court ordered in person visitation due to COVID-19 and believe the
11 order is more restrictive than is necessary under the current public health guidelines.

12 10. I believe that in-person family visitation between children in out-of-home care
13 and their parents/guardians, and/or siblings, can be accomplished on a case-by-case basis,
14 within the current stay at home public health directives, and would be more ideal than a
15 blanket order suspending all in person visits.

16 11. Family visitation between children in out-of-home care and their
17 parents/guardians, and/or siblings, can support children through an unprecedented and
18 challenging time.


19 12. Counties should work to maintain face-to-face visits for children in out-of-home
20 care, especially with youth zero to three, which allow them to continue to develop critical early
21 bonds with their parent, unless there are individual health-related risks that prevent these visits
22 from happening in a safe manner. The individual health-related risks should be evaluated on a
23 case-by-case basis.

24 13. Specifically, in situations where a County social services casework professional
25 determines that in person family visitation between a child in out-of-home care and their
26 parents/guardians, and/or siblings, is best for the child, the County social services casework

1 professional should evaluate the situation in the context of all individuals living in each
2 household, and in consultation with a healthcare professional, to determine if visitation can
3 proceed within the current public health guidelines.
4

5 I declare under penalty of perjury under the laws of the State of California and the United
6 States of America that the foregoing is true and correct.

7 DATED this 2nd day of April, 2020 at Richmond, California.



8
9
10 James Watt, M.D., MPH
11 Acting Deputy Director of the Center for
12 Infectious Diseases and Interim State
13 Epidemiologist
14 California Department of Public Health
15
16
17
18
19
20
21
22
23
24
25
26

Exhibit A

CURRICULUM VITAE

Name: James Watt, MD, MPH

Position: Acting Deputy Director
Acting Chief
Center for Infectious Diseases
California Department of Public Health

Address: Building P, 2nd Floor
850 Marina Bay Parkway
Richmond, CA 94804

Voice: (510) 620-3784
FAX: (916) 440-5678
Email: james.watt@cdph.ca.gov

EDUCATION AND TRAINING

1980-84	Stanford University, Stanford, CA	B.S. (Biology) B.A. (German Studies)
1985	Deutches Primatenzentrum, Goettingen, Germany	Krupp Fellowship
1985-90	University of California, San Diego	M.D.
1990-93	Oakland Children's Hospital, Oakland, CA	Resident (Pediatrics)
1994-95	University of California, Berkeley	M.P.H. (Maternal and Child Health)
1995-96	California Department of Health Services, San Francisco, CA	Resident (Preventive Medicine)

LICENSES, CERTIFICATION

1991-present: Medical Licensure, California
1995-present: Board Certification, Pediatrics

PRINCIPAL POSITIONS HELD

1996-99 Public Health Medical Officer II
Immunization Branch
Division of Communicable Disease Control
California Department of Health Services

1999-01 Epidemic Intelligence Service Officer
Respiratory Diseases Branch
Division of Bacterial and Mycotic Diseases
National Center for Infectious Disease
Centers for Disease Control and Prevention

2001-06 Assistant Scientist
Department of International Health
School of Public Health

4/2/2020

Curriculum Vitae
James Watt, MD, MPH

Johns Hopkins University

2006-07 Public Health Medical Officer III (Epidemiology)
Tuberculosis Control Branch
Division of Communicable Disease Control
Center for Infectious Diseases
California Department of Public Health

2008-10 Chief
Tuberculosis Control Branch
Division of Communicable Disease Control
Center for Infectious Diseases
California Department of Public Health

2010-2019 Chief
Division of Communicable Disease Control
Center for Infectious Diseases
California Department of Public Health

2020-present Acting Deputy Director
Acting Chief
Center for Infectious Diseases
California Department of Public Health

OTHER POSITIONS HELD CONCURRENTLY

2006-present Associate
Johns Hopkins University
School of Public Health

2009-present Clinical Professor
University of California, San Francisco
School of Medicine

2009-2010 Member representing high incidence jurisdictions
Board of Directors
National Tuberculosis Controllers Association

2008-2010 Executive Committee (ex officio)
California Tuberculosis Controllers Association

2012-2019 Deputy State Epidemiologist
California Department of Public Health

2015 Acting State Health Officer, California

2020-present Interim State Epidemiologist
California Department of Public Health

HONORS AND AWARDS

1984	Phi Beta Kappa, Stanford University
2000	United States Public Health Service Achievement Medal
2001	Honor Award, National Center for Infectious Diseases
2002	Committee recognition award for two outstanding abstracts, International Symposium on Pneumococci and Pneumococcal Disease
2015	Outstanding Achievement Award, California Department of Public Health
2016	Outstanding Achievement Award, California Department of Public Health
2019	Outstanding Achievement Award, California Department of Public Health

INVITED PRESENTATIONS

INTERNATIONAL

International Symposium on the Global Reduction of Hib Disease; Scottsdale, Arizona, 2002 (invited talk)
 Indian Academy of Pediatrics Meeting (Pedicon); Calcutta, 2005 (invited talk)
 International Symposium on Pneumococci and Pneumococcal Disease; Alice Springs, Australia, 2006 (invited talk)

NATIONAL

National Vaccine Advisory Committee Conference on Pneumococcal Disease Prevention in Adults: Potential Vaccine Strategies; Baltimore, MD, 2003 (invited talk)
 5th National Association of Public Health Laboratories Meeting on Essential Mycobacteriology Services; San Diego, CA, 2008 (invited talk)
 Francis J. Curry National Tuberculosis Center National Web Training--Practical Applications of Genotyping in Tuberculosis Control; San Francisco, CA, 2008 (invited talk)

ADVISORY PANELS

Immunization Partnership, American Academy of Pediatrics/California Department of Health Services
 Preventive Medicine Residency Advisory Committee, California Department of Health Services
 Cost effectiveness of Hib conjugate vaccine in Egypt, Egyptian Ministry of Health and Population, WHO Eastern Mediterranean Regional Office, and CDC
 A tool for rapidly assessing Hib disease burden, WHO
 Standardized interpretation of chest radiographs for the diagnosis of pneumonia, WHO
 Research Advisors, Pneumococcal Accelerated Development and Implementation Program
 Estimating the burden of *Haemophilus influenzae*, type b in India, Indian Council for Medical Research
 Estimating the global burden of Hib and pneumococcal disease, WHO
 Development of guidelines for the control of tuberculosis in foreign born persons, CDC
 Expert Group to Evaluate Molecular Drug Susceptibility Testing, NTCA

INTERNATIONAL CONSULTATIONS

2001	Estimating Hib disease burden, WHO Africa Regional Office personnel. Harare, Zimbabwe.
2002	Options for Assessing Disease Burden due to Hib in Mongolia, WHO Western Pacific Regional Office, Ulaan Baatar, Mongolia.
2004	Evaluation of Surveillance for Invasive Hib Disease in Mongolia, WHO Western Pacific Regional Office, Ulaan Baatar, Mongolia.
2011-12	Review of evidence on the effectiveness of different Hib conjugate vaccine schedules, WHO Secretariat, Geneva, Switzerland

TEACHING AND MENTORING

COURSES TAUGHT (Johns Hopkins University)

Introduction to Quantitative and Qualitative Research for American Indian Health (Summer Institute, 2006, Principal Instructor. Enrollment of 20).

Collecting, Analyzing and Using Public Health Data in Native American Communities (Summer Institute, 2005, Principal Instructor. Enrollment of 30).

Collecting, Analyzing and Using Public Health Data in Native American Communities (Summer Institute, 2004, Principal Instructor. Enrollment of 36).

COURSES TAUGHT (UC Berkeley)

Public Health in Practice: Communicable Disease Control in California (School of Public Health Spring Semester, 2019, Instructor. Enrollment of 40.)

STUDENTS MENTORED (Johns Hopkins University)

Aparna Roy (MPH, 2005)

Capstone Project Title: *Incidence of community acquired pneumonia in adults.*

Cecilia Young Kwak (MPH, 2004)

Capstone Project Title: *The incidence of community acquired pneumonia in adults: a literature review*

Laurel Murrow (medical student, summer internship 2003)

Project Title: *Evaluation of an Active, Laboratory-based Surveillance System for Invasive Bacterial Infections among the Navajo and White Mountain Apache*

Dahlia McGregor, MD (MPH, 2003)

Integrating Experience Title: *Population-based surveillance of invasive pneumococcal disease in Jamaican children: Providing data for cost-benefit analysis of conjugate pneumococcal vaccines*

FELLOWS MENTORED (CDPH)

Jessica Cunningham, MPH (CSTE fellow)

Major Project: Epidemiology of tuberculosis among homeless persons in California.

Darryl Kong, MPH (Cal-EIS fellow)

Major Project: Identification and management of tuberculosis patients co-infected with HIV in California.

Erin Murray, PhD (CDC EIS Officer)

Major Project: Identification of geographic areas with increased incidence of tuberculosis.

Jonathan Nunez, MD (CDC EIS Officer)

Major Project: Analysis of the impact of non-screening of immigrants prior to arrival on imported tuberculosis in the United States

Patrick Ayscue, DVM, PhD (CDC EIS Officer)

Major Project: Analysis of trends in hospitalization for Varicella and Zoster in California

Jacklyn Wong, PhD (CDC EIS Officer)

Increased tuberculosis risk among immigrants arriving to California with abnormal domestic chest radiographs.

Hope Biswas, PhD (CDC EIS Officer)

Major Project: Characteristics associated with delivery of an infant with congenital syphilis and missed opportunities for prevention—California 2012-2014.

Yasser Bakhsh, MD, MPH (CDC EIS Officer)

Major Project: Area based socioeconomic risk factors for tuberculosis in California.

Caterina Liu, MD (UCSF Resident)

Major Project: Homelessness and Infectious Disease in California

RESEARCH AND CREATIVE ACTIVITIES

RESEARCH AWARDS AND GRANTS

1. California Emerging Infections Program (co-director)
Centers for Disease Control and Prevention 1/1/12-present
2. Cooperative Agreement for Epidemiology and Laboratory Capacity (principal investigator)
Centers for Disease Control and Prevention 1/1/11-present
3. Determination of HIV status and prevalence of HIV co-infection among tuberculosis cases in California (co-principal investigator)
Centers for Disease Control and Prevention 7/1/09-6/31/10
4. Cooperative Agreement for Tuberculosis Prevention, Control and Elimination in the United States (principal investigator)
Centers for Disease Control and Prevention. 1/1/08-12/31/10
5. Hib Initiative (co-investigator)
Global Alliance for Vaccines and Immunization (GAVI)
Supporting evidence-based decision making about *Haemophilus influenzae*, type b (Hib) vaccine use in developing countries 9/1/04-7/31/06
6. India Hib Disease Burden Project (project lead)
GAVI, USAID, Government of India 9/1/04-7/31/06
Estimating the burden of Hib disease in India to support an evidence-based decision about vaccine use
7. Indirect effects of pneumococcal conjugate vaccine in the community (co-investigator)
Wyeth Lederle Vaccines 1/1/00-12/31/03
8. Epidemiology of pneumococcal pneumonia among Navajo and Apache adults (co-investigator)
Aventis 1/1/01-12/31/04
9. Safety and Efficacy of Pentavalent (G1, G2, G3, G4 and P1) Human-Bovine Reassortant Rotavirus Vaccine in Healthy Infants (co-investigator)
Merck & Co. 1/1/01-12/31/04
10. Pneumonia Epidemiology in White Mountain Apache Adults (principal investigator)
NIH/NIGM RO1 (under grant U26 94 00012-01) 9/1/03-8/31/04

11. A Phase 3 Study of MEDI-524 (Numax™), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prevention of RSV Disease Among Navajo and White Mountain Apache Infants (co-investigator) 1/1/04-7/31/06
MedImmune, Inc.

PUBLICATIONS

1. Kahane SM, **Watt JP**, Newell K, Kellam S, Wight S, Smith NJ, et al. Immunization Levels and Risk Factors for Low Immunization Coverage Among Private Practices. *Pediatrics* 2000;105(6):e73.
2. Hyde TB, Gilbert M, Zell ER, **Watt JP**, Schwartz SB, Thacker WL, et al. Azithromycin prophylaxis during a hospital outbreak of *Mycoplasma pneumoniae* pneumonia. *Journal of Infectious Disease* 2001;183:907-12.
3. **Watt JP**, Schuchat A, Erickson K, Honig JE, Gibbs R, Schulkin J Group B Streptococcal Prevention Practices of Obstetrician-Gynecologists. *Obstetrics and Gynecology* 2001;98(1):7-13.
4. Benin AL, O'Brien KL, **Watt JP**, Reid R, Zell ER, Katz S, Donaldson C, Parkinson A, Schuchat A, Santosham M, Whitney CG. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults. *Journal of Infectious Diseases* 2003;188(1):81-9.
5. **Watt JP**, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting. *Journal of Pediatrics* 2003;143(6 Suppl):S163-87.
6. **Watt JP**, O'Brien KL, Benin AL, Whitney CG, Robinson K, Parkinson AJ, Reid R, Santosham M. Invasive Pneumococcal Disease among Navajo Adults, 1989-1998. *Clinical Infectious Diseases* 2004;38(4):496-501.
7. Feikin DR, Nelson CB, **Watt JP**, Mohsni E, Wenger JD, Levine OS. Rapid Assessment Tool for *Haemophilus influenzae*, type b Disease in Developing Countries. *Emerging Infectious Diseases* 2004;10(7):1270-6.
8. **Watt JP**, O'Brien KL, Katz S, Bronsdon MA, Elliott J, Dallas J, Perilla MP, Reid R, Murrow L, Facklam R, Santosham M, Whitney CG. Nasopharyngeal versus Oropharyngeal Sampling for Detection of Pneumococcal Carriage in Adults. *Journal of Clinical Microbiology* 2004;42(11):4974-6.
9. O'Brien KL, Shaw J, Weatherholtz R, Reid R, **Watt J**, Croll J, Dagan R, Parkinson AJ, Santosham M. Epidemiology of invasive Streptococcus pneumoniae among Navajo children in the era before use of conjugate pneumococcal vaccines, 1989-1996. *American Journal of Epidemiology*. 2004;160(3):270-8.
10. Millar EV, O'Brien KL, **Watt JP**, Lingappa J, Pallipamu R, Rosenstein N, Hu D, Reid R, Santosham M. Epidemiology of Invasive Haemophilus influenzae Type a Disease among Navajo and White Mountain Apache Children, 1988-2003. *Clinical Infectious Disease*. 2005;40(6):823-30.
11. Benin AL, **Watt JP**, O'Brien KL, Zell E, Donaldson C, Schuchat A, Santosham M. Delivering Pneumococcal Vaccine to a High Risk Population: The Navajo Experience. *Human Vaccines*. 2005;1(2):e2-5.
12. Chandran A, **Watt JP**, Santosham M. Prevention of *Haemophilus influenzae* Type b (Hib) Disease: Past Success and Future Challenges. *Expert Review of Vaccines*. 2005;4(6):819-27.
13. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CDC, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi

- BA, Marshall GS, Gothefors L, Campens D, Karvonen A, **Watt JP**, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit, PA, Heaton, PM. Safety and Efficacy of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine. *New England Journal of Medicine*. 2006;354(1):23-33.
14. Millar EV, O'Brien KL, **Watt JP**, Bronsdon MA, Dallas J, Witney CG, Reid R, Santosham M. Effect of community wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. *Clinical Infectious Disease*. 2006;43(1):8-15.
15. Moisi JC, Levine OS, **Watt JP**. Sensitivity of Surveillance for *Haemophilus influenzae*, type b Meningitis. *Pediatric Infectious Disease Journal*. 2006;25(10):960.
16. **Watt JP**, O'Brien KL, Benin AL, McCoy SI, Donaldson CM, Reid R, Schuchat A, Zell ER, Hochman M, Santosham M, Whitney CG. Risk Factors for Invasive Pneumococcal Disease Among Navajo Adults. *American Journal of Epidemiology*. 2007 Nov 1;166(9):1080-7.
17. Hochman ME, **Watt JP**, Reid R, O'Brien KL. The Prevalence of End Stage Renal Disease in Native American Adults on the Navajo Reservation. *Kidney International*. 2007;71(9):931-7.
18. Rossi I, Zuber P, Dumolard L, Walker D, **Watt JP**. Introduction of Hib vaccine into national immunization programmes: a descriptive analysis of global trends. *Vaccine*. 2007;25:7075-80.
19. Santosham M, Reid R, Chandran A, Millar EV, **Watt JP**, Weatherholtz R, Donaldson C, Croll J, Moulton LH, Thompson CM, Siber GR, O'Brien KL. Contributions of Native Americans to the global control of infectious diseases. *Vaccine*. 2007;22:2366-74.
20. Menzies R, McIntyre P, Reid R, O'Brien K, Santosham M, **Watt JP**, et al. Vaccine preventable diseases in indigenous populations—International perspectives. *Vaccine*. 2007;25:7281-4.
21. Millar EV, **Watt JP**, Bronsdon MA, Dallas J, Reid R, Santosham M, O'Brien KL. Indirect effect of 7-valent pneumococcal conjugate vaccine (Pnc7-CRM) on pneumococcal colonization among unvaccinated household members. *Clinical Infectious Disease*. 2008;47(8):989-96.
22. Mendsaikhan J, **Watt JP**, Mansoor O, Suvdmaa N, Edmond K, Litt DJ, Nymadawa P, Baoping Y, Altantsetseg D, Slack M. Childhood Bacterial Meningitis in Ulaanbaatar, Mongolia, 2002-2004. *Clinical Infectious Disease*. 2009;48(S2):S141-146.
23. Wolfson LJ, O'Brien KL, **Watt JP**, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Methods to estimate the global burden of disease due to *Haemophilus influenzae* type b and *Streptococcus pneumoniae* in children less than 5 years of age. *Lancet*. 2009; published online.
24. O'Brien KL, Wolfson LJ, **Watt JP**, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. The global burden of disease due to *Streptococcus pneumoniae* in children less than 5 years of age. *Lancet*. 2009;374:893-902.
25. **Watt JP**, Wolfson LJ, O'Brien KL, Henkle E, Deloria-Knoll M, McCall N, Lee E, Levine OS, Hajjeh R, Mulholland K, Cherian T. The global burden of disease due to *Haemophilus influenzae*, type b in children less than 5 years of age. *Lancet*. 2009;374:903-911.
26. **Watt JP**, Moisi JC, Donaldson RLA, Reid R, Ferro S, Whitney CG, Santosham, M, O'Brien KL. Measuring the Incidence of Community Acquired Pneumonia in a Native American Community. *Epidemiology and Infection*. 2010; 138:1146-54.

27. **Watt JP**, Moïsi JC, Donaldson RLA, Reid R, Ferro S, Whitney CG, Santosham M, O'Brien KL. Use of serology and urine antigen detection to estimate the proportion of adult community-acquired pneumonia attributable to *Streptococcus pneumoniae*. *Epidemiology and Infection*. 2010;138:1796-803
28. Gupta M, Kumar R, Deb AK, Bhattacharya SK, Bose A, John J, Balraj V, Ganguly NK, Kant L, Kapoor AN, **Watt J**, Shearer J, Santosham M. Multi-center surveillance for pneumonia and meningitis in children. *Indian J Med Res*. 2010;131:649-58.
29. Banerjee R, Allen J, Lin SYG, Westenhause J, Desmond E, Schechter GF, Scott C, Raftery A, Mase S, **Watt JP**, Flood J. Rapid Drug Susceptibility Testing with a Molecular Beacon Assay Is Associated with Earlier Diagnosis and Treatment of Multidrug-Resistant Tuberculosis in California. *J Clin Microbiol*. 2010;48(10):3779-81.
30. Metcalfe J, Facer M, Damesyn M, Xia Q, **Watt J**, Hill J, Hopewell P, Westenhause J, Flood J. Evolution of tuberculosis/HIV co-infection in California during the HAART Era, 1996-2007. *Retrovirology*. 2010;7(Suppl):01.
31. Fitzwater S, **Watt JP**, Levine OS, Santosham M. *Haemophilus influenzae* type B conjugate vaccines: considerations for vaccination schedules and implications for developing countries. *Human Vaccines*. 2010;6:810-8.
32. Lowenthal P, Westenhause J, Moore M, Posey DL, **Watt JP**, Flood J. Reduced importation of tuberculosis after the implementation of an enhanced pre-immigration screening protocol. *International J Tuberculosis Lung Dis*. 2011;15:761-6.
33. Grant LR, Gentsch JR, Esona MD, **Watt J**, Reid R, Weatherholtz RC, Santosham M, Parashar UD, O'Brien KL. Detection of G3P[3] and G3P[9] rotavirus strains in American Indian children with evidence of gene reassortment between human and animal rotaviruses. *J Med Virol*. 2011;83:1288-99.
34. Pascopella L, DeRiemer K, **Watt JP**, Flood JM. When tuberculosis comes back: Who develops recurrent tuberculosis in California? *PLoS One* 2011;6:e26541
35. Grant LR*, **Watt JP***, Weatherholtz RC, Moulton LH, Reid R, Santosham M, O'Brien, KL. Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children. *Pediatr Infect Dis J* 2012;31:184-8. *equal contribution
36. Grant L, Vinje J, Parashar U, **Watt J**, Reid R, Weatherholtz R, Santosham M, Gentsch J, O'Brien K. Epidemiologic and Clinical Features of Other Enteric Viruses Associated with Acute Gastroenteritis in American Indian Infants. *J Pediatr* 2012;161:110-5.e1.
37. Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, **Watt JP**, Chavez G. California Pertussis Epidemic, 2010. *J Pediatr* 2012;161:1091-6.
38. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL, AGEDD Adult Pneumococcal Burden Study Team (**Watt JP** study team member). Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. *PLoS One* 2013;8(4):e60273.
39. Kong D, **Watt JP**, Marks S, Flood J. HIV Status Determination Among Tuberculosis Patients From California During 2008. *J Public Health Management Practice* 2013;19:169-77.
40. Grant J, **Watt J**, Moulton L, Weatherholtz R, Reid R, Santosham M, O'Brien K. Lack of non-specific protection against all-cause, non-rotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine. *J Pediatr Gastroent Nutr* 2013; epub ahead of print.

41. Murray EL, Samuel MC, Brodsky J, Akiba CF, King C, Li M, Wollesen M, Gonzales PE, **Watt JP**, Bolan G. *Neisseria gonorrhoeae* Outbreak: Unintended Consequences of Electronic Medical Records and Using an Out-of-State Laboratory—California, July 2009-February 2010. *Sex Trans Dis* 2013;40:556-8.
42. Metcalfe JZ, Porco TC, Westenhouse J, Damesyn M, Facer M, Hill J, Xia Q, **Watt JP**, Hopewell PC, Flood J. Tuberculosis and HIV co-infection, California, USA, 1993–2008. *Emerg Infect Dis* 2013; 19:400-6.
43. Scott S, Altanseseg D, Sodbayer D, Nymadawa P, Bulgan D, Mendsaikhan J, **Watt JP**, Slack M, Carvalho MG, Hajjeh R, Edmond KM. Impact of Haemophilus influenzae Type b Conjugate Vaccine in Mongolia: Prospective Population-Based Surveillance, 2002-2010. *J Peds* 2013;163(1 Suppl):S8-11.
44. Núñez JJ, Fritz CL, Knust B, Buttke D, Enge B, Novak MG, Kramer V, Osadebe L, Messenger S, Albariño CG, Ströher U, Niemela M, Amman BR, Wong D, Manning CR, Nichol ST, Rollin PE, Xia D, **Watt JP**, Vugia DJ. An Outbreak of Hantavirus Infections Among Overnight Visitors to Yosemite National Park, California, USA, 2012. *Emerg Infect Dis* 2014;20(3):386-93.
45. Kong D, **Watt JP**, Marks SM, Flood JM. Timely HIV Diagnosis and HIV/TB Comanagement among California Patients in 2008. *Publ Health Rep* 2014;129:170-7.
46. Ayscue P, Murray E, Uyeki T, Zipprich J, Harriman K, Salibay C, Kang M, Luu A, Glenn-Finer R, **Watt J**, Glaser C, Louie J. Influenza-Associated Intensive-Care Unit Admissions and Deaths—California, September 29, 2013—January 18, 2014. *MMWR* 2014;63(7):143-7.
47. Winter K, Glaser C, Watt J, Harriman K. Pertussis epidemic—California, 2014. *MMWR* 2014;63(48):1129-32.
48. Ayscue P, Van Haren K, Sheriff H, Waubant E, Waldron P, Yagi S, Yen C, Clayton A, Padilla T, Pan C, Reichel J, Harriman K, Watt J, Sejvar J, Nix WA, Feikin D, Glaser C. Acute flaccid paralysis with anterior myelitis—California, June 2012-June 2014. *MMWR* 2014;63(40):903-6.
49. Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, Federman S, Stryke D, Anterson C, Yagi S, Messenger S, Wadford D, Xia D, **Watt JP**, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14): a retrospective cohort study. *Lancet Infect Dis* 2015; epub March 31.
50. Shahkarami M, Yen C, Glaser C, Xia D, **Watt J**, Wadford DA. Laboratory Testing for Middle East Respiratory Syndrome Coronavirus, California, USA, 2013-2014. *Emerg Infect Dis* 2015;21(9):epub.
51. Zipprich J, Winter K, Hacker J, Xia D, **Watt J**, Harriman K. Measles outbreak—California, December 2014-February 2015. *MMWR* 2015;64(6):153-4.
52. Smith EM, Khan MA, Reingold A, **Watt JP**. Group B streptococcus infections of soft tissue and bone in California adults, 1995-2012. *Epidemiol Infect* 2015;143(15):3343-50.
53. Van Haren K, Ayscue P, Waubant E, Clayton A, Sheriff H, Yagi S, Glenn-Finer R, Padilla T, Strober, JB, Aldrovandi G, Wadford DA, Chiu, CY, Xia D, Harriman K, **Watt JP**, Glaser Ca. Acute flaccid myelitis of unknown etiology in California, 2012-2015. *JAMA* 2015; 314(24):2663-71.
54. Langley G, Hao Y, Pondo T, Miller L, Petit, S, Thomas A, Lindegren ML, Farley MM, Dumyati G, Como-Sabetti K, Harrison LH, Baumbach J, **Watt J**, Van Beneden C. The Impact of Obesity and Diabetes on the Risk of Disease and Death due to Invasive Group A *Streptococcus* Infections in Adults. *Clin Infect Dis* 2016;62(7):845-52.

55. Nelson GE, Pondo T, Toews K, Farley MM, Lindegren ML, Lynfield R, Aragon D, Zansky SM, **Watt JP**, Cieslak PR, Angeles K, Harrison LH, Petit S, Beall B, Van Beneden CA. The Epidemiology of Invasive Group A Streptococcal Infection in the United States, Implications for Vaccine Prevention. *Clin Infect Dis* 2016; epub April 22.
56. Barry PM, Kay AW, Flood JM, **Watt J**. Getting to Zero: Tuberculosis Elimination in California. *Curr Epidemiol Rep* 2016; epub March 29.
57. Kozyreva VK, Jospin G, Greninger AL, **Watt JP**, Eisen JA, Chaturvedi V. Recent Outbreaks of Shigellosis in California Caused by Two Distinct Populations of *Shigella sonnei* with either Increased Virulence or Fluoroquinolone Resistance. *mSphere* 2016;1(6); e00344-16.
58. Blain AE, Lewis M, Banerjee E, Kudish K, Liko J, McGuire S, Selvage D, **Watt J**, Martin SW, Skoff TH. An Assessment of the Cocooning Strategy for Preventing Infant Pertussis—United States, 2011. *Clin Infect Dis* 2016;63(suppl 4):S221-S226.
59. Skoff TH, Blain AE, **Watt J**, Scherzinger K, McMahon M, Zansky SM, Kudish K, Cieslak PR, Lewis M, Shang N, Martin SW. Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation. *Clin Infect Dis* 2017; epub 2017.
60. Wong J, Lowenthal P, Flood J, **Watt J**, Barry PM. Increased tuberculosis risk among immigrants arriving to California with abnormal domestic chest radiographs. *Intl J Tuberculosis Lung Dis* 2018;22(1):73-79
61. Biswas HH, Ng RA, Murray EL, Chow JM, Stoltey JE, **Watt JP**, Bauer HM. Characteristics Associated with Delivery of an Infant with Congenital Syphilis and Missed Opportunities for Prevention—California, 2012-2014. *Sexually Trans Dis*. 2018;45(7):435-441.
62. Porse CC, Messenger S, Vugia DJ, Jilek W, Salas W, **Watt J**, Kramer V. Travel-Associated Zika Cases and the Threat of Local Zika Transmission in California during the Global Zika Outbreak. *Emerging Infect Dis*. 2018;24(2):1626-32.
63. Pitts SI, Maruthur NM, Langley GE, Pondo T, Shutt KA, Hollick R, Schrag SJ, Thomas A, Nichols M, Farley M, **Watt JP**, Miller L, Schaffner W, Holtzman C, Harrison LH. Obesity, Diabetes, and the Risk of Invasive Group B Streptococcal Disease in Nonpregnant Adults in the United States. *Open Forum Infect Dis*. 2018;5(6):ofy030.
64. Francois Watkins LK, McGee L, Schrag SJ, Beall B, Jain JH, Pondo T, Farley MM, Harrison LH, Zansky SM, Baumbach J, Lynfield R, Snippes Vagnone P, Miller LA, Schaffner W, Thomas AR, **Watt JP**, Petit S, Langley GE. Epidemiology of Invasive Group B Streptococcal Infections among Nonpregnant Adults in the United States, 2008-2016. *JAMA Intern Med*. 2019; epub ahead of print.
65. Abedi GR, Messacar K, Luong W, Nix WA, Rogers S, Queen K, Tong S, Oberste MS, **Watt J**, Rothrock G, Dominguez S, Gerber SI, Watson JT. Picornavirus etiology of acute infections among hospitalized infants. *J Clin Virology*. 2019;116:39-43.

BOOKS AND CHAPTERS

1. Chandran A, **Watt JP**, Santosham M. Chapter 11: *Haemophilus influenzae* Vaccines. Plotkin SA, Orenstein WA, Offit PA, Editors. *Vaccines*. Fifth edition. Philadelphia: W.B. Saunders Co. 2007.
2. Chandran A, **Watt JP**, Santosham M. Chapter 11: *Haemophilus influenzae* Vaccines. Plotkin SA, Orenstein WA, Offit PA, Editors. *Vaccines*. Sixth edition. Philadelphia: W.B. Saunders Co. 2012.

OTHER PUBLICATIONS

1. Estimating the local burden of *Haemophilus influenzae* type b (Hib) disease preventable by vaccination. WHO/V&B/01.27. World Health Organization, Geneva, 2001. (*contributor*)
2. Expert review of a tool for rapidly assessing *Haemophilus influenzae* type b (Hib) disease burden. WHO/V&B/01.25. World Health Organization, Geneva, 2001. (*rapporteur/primary author of meeting summary*)
3. Centers for Disease Control and Prevention. Adoption of Perinatal Group B Streptococcal Disease Prevention Recommendations by Prenatal-Care Providers--Connecticut and Minnesota, 1998. *MMWR* 2000;49(11):228-31. (*primary author*)
4. Global Literature Review of *Haemophilus influenzae* type b and *Streptococcus pneumoniae* invasive disease among children less than five years of age, 1980-2005. World Health Organization, Geneva, 2008. (*co-author*)
5. Centers for Disease Control and Prevention. Notes from the Field: Hantavirus Pulmonary Syndrome in Visitors to a National Park—Yosemite Valley, California, 2012. *MMWR* 2012;61(46):952. (*co-author*)
6. Centers for Disease Control and Prevention. Mumps Outbreak on a University Campus, 2011. *MMWR* 2012;61:986-9. (*co-author*)